Thymosin α1 in melanoma: From the clinical trial setting to the daily practice and beyond

Annals of the New York Academy of Sciences

Volumn 1270, Issue 1, 2012, Pages 8-12

  Danielli, Riccardo ^a   Fonsatti, Ester ^a   Calabrò, Luana ^a   Giacomo, Anna Maria Di ^a   Maio, Michele ^a  

^a UNIVERSITY HOSPITAL OF SIENA   (Italy)

Author keywords

Dacarbazine; Immunotherapy; Melanoma; Thymosin 1

Indexed keywords

ALPHA INTERFERON; DACARBAZINE; THYMOSIN ALPHA1;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; DISEASE COURSE; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOPHENOTYPING; LEWIS CARCINOMA; LYMPHOCYTE DIFFERENTIATION; MELANOMA; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; UPREGULATION;

EID: 84867370942     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2012.06757.x     Document Type: Article

References (23)

1. Lui, P. et al. 2007. Treatments for metastatic melanoma: synthesis of evidence from randomized trials. Cancer Treat. Rev. 33: 665-680.
2. Korn, E.L. et al. 2008. Meta-Analysis of Phase II Cooperative Group Trials in Metastatic Stage IV Melanoma to Determine Progression-Free and Overall Survival Benchmarks for Future Phase II Trials. J. Clin. Oncol. 4: 527-534.
3. Kirkwood, J.M. et al. 2008. Next generation of immunotherapy for melanoma. J. Clin. Oncol. 26: 3445-3455.
4. Sznol, M. 2012. Advances in the treatment of metastatic melanoma: new immunomodulatory agents. Semin. Oncol. 39: 192-203.
5. Kudchadkar, R. et al. 2012. Targeting mutant BRAF in melanoma: current status and future development of combination therapy strategies. Cancer J. 18: 124-131.
6. Hodi, F.S. et al. 2010. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363: 711-723.
7. Chapman, P. et al. 2011. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 364: 2507-2516.
8. Robert, C. et al. 2011. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N. Engl. J. Med. 364: 2517-2526.
9. Di Giacomo, A.M. et al. 2012. A phase II, open label, single-arm study to investigate the combination of ipilimumab and fotemustine in patients with advanced melanoma: the NIBIT-M1 trial. Lancet Oncol. 13: 879-886.
10. Garaci, E. et al. 1995. Sequential chemoimmunotherapy for advanced non-small cell lung cancer using cisplatin, etoposide, thymosin-alpha 1 and interferon-alpha 2a. Eur. J. Cancer. 31A: 2403-2405.
11. Maio, M. et al. 2010. Large randomized study of thymosin alpha 1, interferon alfa, or both in combination with dacarbazine in patients with metastatic melanoma. J. Clin. Oncol. 28: 1780-1787.
12. Garaci, E. et al. 1990. Combination treatment using thymosin alpha one and interferon after cyclophosphamide is able to cure Lewis lung carcinoma in mice. Cancer Immunol. Immunother. 32: 154-160.
13. Rasi, G. et al. 1994. Anti-tumor effect of combined treatment with thymosin alpha 1 and interleukin-2 after 5-fluorouracil in liver metastase from colorectal cancer in rats. Int. J. Cancer. 57: 701-705.
14. Giuliani, C. et al. 2000. Thymosin-alpha1 regulates MHC class I expression in FRTL-5 cells at transcriptional level. Eur. J. Immunol. 30: 778-786.
15. Sinibaldi Vallebona, P. et al. 2002. Thymalfasin up-regulates tumor antigen expression in colorectal cancer cells. Tumour Biol. 23: 45.
16. Balch, C.M. et al. 2001. Prognostic factor analysis of 17, 600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J. Clin. Oncol. 19: 3622-3634.
17. Eggermont, A.M. et al. 2008. Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomized phase III trial. Lancet 12: 117-26.
18. Wolchok, J.D. et al. 2009. Guidelines for evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin. Cancer Res. 15: 7412-7420.
19. Danielli, R. et al. Single-centre experience of thymosin alpha-1 and dacarbazine in advanced melanoma: results from an Italian compassionate-use programme. In preparation.
20. Di Giacomo, A.M. et al. 2011. Ipilimumab experience in heavely pretreated patients with melanoma in an expanded access program at the University Hospital of Siena (Italy). Cancer Immunol. Immunother. 60: 467-477.
21. Romani, L. et al. 2006. Thymosin alpha1 act tryptophan catabolism and estabilishes a regulatory environment for balance of inflammation and tolerance. Blood 108: 2265-2274.
22. Haynes, N.M. et al. 2008. Immunogenic anti-cancer chemotherapy as an emerging concept. Curr. Opin. Immunol. 20: 545-557.
23. Krieg, A.M. et al. 2008. Toll-like receptor 9 (TLR9) agonists in the treatment of cancer. Oncogene 27:161-167.